nesvacumab
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2011 (NCT01271972)
Timeline
Indications
Mechanism of action
- Angiopoietin-2INHIBITOR
ANGPT2 inhibitor
It blocks the binding of Ang2 (an important regulator of tumor angiogenesis and growth) to Tie 2 (with an IC50 of approximately 60 pmol/L) decreasing its activity, which causes inhibition of tumor growth. Ang2 expression is upregulated in a range of human cancers, and high levels of circulating Ang2 are associated with a poor prognosis.
high-affinity binding (KD ~ 18 pmol/L for human Ang2)
VPS51 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNesvacumab ↗
- ChEMBLCHEMBL2109297 ↗
- ChEMBLCHEMBL2108678 ↗
Also known as
- nesvacumab
- nesvacumab
- regn910
- regn-910
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02712008 | Phase 2 | Mar 1, 2016 | Regeneron |
| NCT02713204 | Phase 2 | Feb 1, 2016 | Regeneron |
| NCT01997164 | Phase 1 | Nov 1, 2014 | Regeneron |
| NCT01688960 | Phase 1 | Oct 1, 2012 | Regeneron, Sanofi |
| NCT01271972 | Phase 1 | Jan 1, 2011 | Regeneron, Sanofi |